It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The maker of the experimental Ebola drug that was given to two infected Americans said Monday that its supply has been exhausted after the company provided doses to a West African nation.
Mapp Biopharmaceutical Inc. said in a brief online statement it had complied with every request for the drug that had the necessary legal and regulatory authorization. The company said it provided the drug, called ZMapp, at no cost in all cases.
San Diego-based Mapp didn't name any countries that requested the drug and didn't release additional details.
August 12, 2014 at 8:30 AM - The available supply of ZMapp™ has been exhausted. We have complied with every request for ZMapp™ that had the necessary legal/regulatory authorization. It is the requestors’ decision whether they wish to make public their request, acquisition, or use of the experimental drug. Any decision to use ZMapp™ must be made by the patients’ medical team. Drug has been provided at no cost in all cases.
Mapp, in its statement, didn’t identify which countries had received the remaining doses. The company said those who requested the drug can reveal their acquisition or use of the experimental drug.
Mapp and its partners, Defyrus Inc. and a subsidiary of Reynolds American Inc., are working with the U.S. government to quickly increase production, the company said.
“Additional resources are being brought to bear on scaling up,” the company said. “The emergency use of an experimental medicine is a highly unusual situation.”
originally posted by: Vasa Croe
You know....another thing that doesn't add up to me is that they state on their site that they gave it away at no cost. Also, for a company with so much publicity right now, they seem like extremely small potatoes (from their poorly built website) to be able build a vaccine like this.
Mapp
August 12, 2014 at 8:30 AM - The available supply of ZMapp™ has been exhausted. We have complied with every request for ZMapp™ that had the necessary legal/regulatory authorization. It is the requestors’ decision whether they wish to make public their request, acquisition, or use of the experimental drug. Any decision to use ZMapp™ must be made by the patients’ medical team. Drug has been provided at no cost in all cases.
Hell....according to Hoover's they are less than a million dollar company. How can they afford to give this stuff away?
DTRA is the U.S. Department of Defense’s official Combat Support Agency for countering weapons of mass destruction. Our people are Subject Matter Experts on WMD, and we address the entire spectrum of chemical, biological, radiological, nuclear and high yield explosive threats. DTRA’s programs include basic science research and development, operational support to U.S. warfighters on the front line, and an in-house WMD think tank that aims to anticipate and mitigate future threats long before they have a chance to harm the United States and our allies. SCC-WMD, the U.S. Strategic Command Center for Combating Weapons of Mass Destruction, synchronizes Combating Weapons of Mass Destruction efforts across our military’s geographic commands and leverages the people, programs and interagency relationships of DTRA at a strategic level. We work with the military services, other elements of the United States government, and countries across the planet on counterproliferation, nonproliferation and WMD reduction issues with one goal in mind: Making the World Safer.
Weapons of mass destruction - chemical, biological, radiological and nuclear - and high yield explosives can pose deadly and destructive threats to U.S. security. Through its support to the Office of the Secretary of Defense and to combatant commanders, DTRA works to stop the spread, counter the effects, and prepare for the use of weapons of mass destruction. By making WMD less effective or completely ineffective, we limit their appeal to our adversaries and their potential use as tools of war, provide U.S. forces freedom of action, and protect the homeland.
originally posted by: Mianeye
a reply to: Vasa Croe
Probably because they know what they are doing and have a lot of knowledge, doesn't have to do with anything WMD...
originally posted by: MystikMushroom
a reply to: Vasa Croe
That sure is one ghetto website for a company that can save people's lives from Ebola!
Holy cow, I've seen 13 year old kids build better websites!
originally posted by: Mianeye
a reply to: Vasa Croe
No, but drastic situation requires drastic measures, if these are the ones with the most knowledge it makes sense to use them, or anyone who is professional enough to handle it...
It's like there is a type of panic in all this because of the fear it spreads rapidly.
originally posted by: Vasa Croe
But they have been involved since well before this occurred.....the graphic I just posted was from 2013 and they are already in pre-clinical trials....this is way before the recent outbreak happened.
originally posted by: MessageforAll
If any of this would be true this company would open up an IPO and the stocks would skyrocket. A company that has the potential of the holy grail on ebola and just gives it for FREE
I know Canadians are Canadians, but that's a stretch.
ZMappTM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available.
ZMapp™ antibodies are being produced under an existing manufacturing collaboration with
Kentucky Bioprocessing (KBP, Owensboro KY). Using a fully automated production system that
operates in accordance with good manufacturing practices (GMP), the antibodies are produced in
Nicotiana. This high performance manufacturing process decreases production time, increases
the quantity of antibody produced, and lowers the cost of manufacturing.